Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$18.86 USD
+0.37 (2.00%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $18.84 -0.02 (-0.11%) 7:12 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.86 USD
+0.37 (2.00%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $18.84 -0.02 (-0.11%) 7:12 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Zacks News
Capricor Therapeutics (CAPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Capricor Therapeutics (CAPR) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 27.27% and -42.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -7.69% and -75.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Capricor Therapeutics (CAPR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -7.69% and -1.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session
by Zacks Equity Research
Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.
Rockwell Medical (RMTI) Looks Good: Stock Moves 5.9% Higher
by Zacks Equity Research
Rockwell Medical, Inc. (RMTI) shares rose almost 6% in the last trading session.